Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | GRN | P28799 | 3/20 | 0.51 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.48 |
| ▸ | LAP3 | P28838 | 3/20 | 0.46 |
| ▸ | FPR2 | P25090 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468410 | 1.00 | ALDH1A1 (0.59) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL3377857 | 1.00 | ALDH1A1 (0.59) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL1666838 | 0.94 | ALDH1A1 (0.53) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL1666833 | 0.94 | ALDH1A1 (0.53) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| Phosphonic Acid SCHEMBL1992439 | 0.92 | ALDH1A1 (0.52) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| Phosphonic Acid SCHEMBL1992436 | 0.92 | ALDH1A1 (0.52) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL30211920 | 0.80 | ALDH1A1 (0.64) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL31163587 | 0.80 | MME (0.54) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL10271737 | 0.79 | ALDH1A1 (0.42) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL93452 | 0.78 | ALDH1A1 (0.61) | ALDH1A1LMNAMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-102176818-A | Antimicrobial gel formulations | NOVABAY PHARMACEUTICALS INC | 2011-09-07 | — | — | CN | claimed |
| EP-2120555-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | Heller, Adam (US) | 2009-11-25 | — | — | EP | claimed |
| US-20080287866-A1 | Methods and compositions for the treatment of pain | HELLER ADAM | 2008-11-20 | — | — | US | claimed |
| WO-2008094664-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | HELLER ADAM (US) | 2008-08-07 | — | — | WO | claimed |
| CN-101132785-A | N-halogenated amino acids and N, N-dihalogenated amino acids in combination with hypohalous acids | NOVABAY PHARMACEUTICALS INC (US) | 2008-02-27 | — | — | CN | claimed |
| US-3991107-A | Haloamine transfer | NATIONAL PATENT DEVELOPMENT CORPORATION (US) | 1976-11-09 | — | — | US | claimed |
| US-12558335-B2 | Preparation for removal and/or prevention of an infection associated with Staphylococcus epidermidis | RLS GLOBAL AB (SE) | 2026-02-24 | — | — | US | disclosed |
| US-20240091121-A1 | PHOSPHONATES AND N-HALAMINES COMPOSITIONS FOR TARTAR REMOVAL | O.Y.M. INNOVATION LTD. (IL) | 2024-03-21 | — | — | US | disclosed |
| EP-4274539-A2 | PHOSPHONATES AND N-HALAMINES COMPOSITIONS FOR TARTAR REMOVAL | O.Y.M. Innovation Ltd. (IL) | 2023-11-15 | — | — | EP | disclosed |
| CN-116710046-A | Phosphonic acid and N-halamine compositions for tartar removal | O.Y.M.创新有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20220339133-A1 | PREPARATION FOR REMOVAL AND/OR PREVENTION OF AN INFECTION ASSOCIATED WITH STAPHYLOCOCCUS EPIDERMIDIS | RLS GLOBAL AB (SE) | 2022-10-27 | — | — | US | disclosed |
| EP-4031125-A1 | PREPARATION FOR REMOVAL AND/OR PREVENTION OF AN INFECTION ASSOCIATED WITH STAPHYLOCOCCUS EPIDERMIDIS | RLS Global AB (SE) | 2022-07-27 | — | — | EP | disclosed |
| EP-2120555-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | Heller, Adam (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080287866-A1 | Methods and compositions for the treatment of pain | HELLER ADAM | 2008-11-20 | — | — | US | disclosed |
| WO-2008094664-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | HELLER ADAM (US) | 2008-08-07 | — | — | WO | disclosed |
| CN-101132785-A | N-halogenated amino acids and N, N-dihalogenated amino acids in combination with hypohalous acids | NOVABAY PHARMACEUTICALS INC (US) | 2008-02-27 | — | — | CN | disclosed |
| CN-1902158-A | N,N-dihalogenated amino acids and derivatives | NOVACAL PHARMACEUTICALS INC (US) | 2007-01-24 | — | — | CN | disclosed |
| US-3991107-A | Haloamine transfer | NATIONAL PATENT DEVELOPMENT CORPORATION (US) | 1976-11-09 | — | — | US | disclosed |
| US-3943628-A | Spoon excavator for applying chemically acting tooth decay attacking fluid | KRONMAN JOSEPH H | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091121-A1 | PHOSPHONATES AND N-HALAMINES COMPOSITIONS FOR TARTAR REMOVAL | PHOSPHO1, PHPT1, PTMS | ALDH1A1 4414/4885LMNA 1066/4885MEN1 4407/4885 |
| US-20080287866-A1 | Methods and compositions for the treatment of pain | ACHE, S100P, P2RX3 | ALDH1A1 2612/4885LMNA 1174/4885MEN1 4763/4885 |
| US-12558335-B2 | Preparation for removal and/or prevention of an infection associated with Staphylococcus epidermidis | CLCN2, CUTA, CCR10 | ALDH1A1 3248/4885LMNA 4204/4885MEN1 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.